The present invention relates to an antibody or an antigen-binding fragment thereof that has improved binding affinity for endothelin receptor type A. The present invention also relates to an antibody or an antigen-binding fragment thereof that has improved productivity. The antibody developed in the present invention is suitable for use in the treatment and diagnosis of diseases associated with endothelin receptor type A due to its remarkably improved binding affinity for the antigen and high productivity compared to conventional antibodies.

Provided is a ROBO1 CAR-NK cell carrying a suicide gene, and a preparation method and application thereof. In order to increase the safety and controllability of a CAR-NK therapy, on the basis of a present ROBO1 CAR-NK cell, a suicide gene switch element is integrated into a genome by means of a lentiviral transfection technology to form a CAR-NK carrying a suicide gene. By adding the suicide gene, the CAR-NK cell can be better controlled, and the clinical safety is further improved.

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Neoantigenic peptides useful for the treatment of MSI-H tumors, vaccines and composition comprising the peptides, and methods of inducing or enhancing an immune response and of treating MSI-H tumors are provided.

The present invention provides an immune enhancer comprising at least an interferon and a granulocyte-macrophage colony-stimulating factor, and an immunotherapeutic pharmaceutical composition comprising at least an antigen and the above-mentioned immune enhancers. The present invention further discloses a preparation method of the immunotherapeutic pharmaceutical composition, the use of the immune enhancer and the immunotherapeutic pharmaceutical composition. The immune enhancer can be applied to disease and tumor treatments caused by viruses, bacteria, and other microorganisms.

Disclosed herein are methods for identifying a subject as having serrated colorectal cancer (CRC), and models of human serrated CRC. Also provided herein are methods for treating serrated CRC in the subject.

The present invention provides a vaccine formulation for use in the prevention and/or treatment of a cancer, comprising a complex of a hyaluronic acid derivative having an introduced hydrophobic group, and an antigen.

The present disclosure provides the gene therapy compositions comprising vectors (e.g., viral vectors) suitable for delivery of nucleic acids encoding immunomodulatory proteins or functional fragments thereof, and methods of using the same. Certain aspects of the disclosure are directed to an adeno-viral vector (AAV) delivery of nucleic acids encoding two or more immunomodulatory proteins or functional fragments thereof to a tumor.

The present invention provides a complex for use in the prevention and/or treatment of cancer, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of cancer, such as a pharmaceutical compositions and vaccines are provided.

The present invention relates, inter alia, to compositions and methods, including chimeric proteins and combination therapies that find use in the treatment of disease, such as cancer and/or an inflammatory disease.